$34.300
+2.545 (+7.42%)收盤時
ALMR 資訊
ALMR 事件
Alamar Biosciences Discovers ALS Blood Signature
Alamar Biosciences announced researchers at Emory University have identified a 10-protein blood signature that distinguished patients with amyotrophic lateral sclerosis from healthy controls with 98.3% balanced accuracy in an independent validation cohort. The study, published in Nature Communications, used Alamar Biosciences' NULISA technology to measure more than 300 neurological and inflammatory proteins in each blood sample. The newly reported signature remains a research finding, not a clinically validated screening or diagnostic test. "ALS patients and their families often wait far too long for answers. We built NULISA to measure low-abundance proteins in blood that other technologies struggle to see, and to measure many of them at once. This study shows why that matters. By profiling brain-derived and inflammatory proteins together, the Emory team identified a multi-protein signature that outperformed single marker testing," said Yuling Luo, founder, CEO and chair of Alamar Biosciences.
Alamar Biosciences Publishes Alzheimer's Study
The company states: "Alamar Biosciences announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer's disease exhibit markedly different biological responses during treatment with lecanemab. Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar's NULISAseq(TM) CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center."
Alamar Biosciences Stock Rises 15.1% to $36.83
Alamar Biosciences is up 15.1%, or $4.82 to $36.83.
Alamar Biosciences Stock Rises 9.4% to $35.02
Alamar Biosciences is up 9.4%, or $3.01 to $35.02.
Alamar Biosciences Expands Partnership with Alzheimer's Disease Data Initiative
Alamar Biosciences announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. The expanded agreement adds profiling of 86,000 plasma samples using the company's newest neurology panel, NULISAseq Neuro 220. Approximately 21,000 samples are part of a national-scale proteomics initiative launched with leading research universities in mid-July. Building on the June 2025 announcement of a multi-center initiative which profiled over 55,000 samples using Alamar's ultra-sensitive NULISA technology, this expansion reflects growing confidence in the partnership's scientific output and the Neuro 220 panel's ability to deliver richer insights into the co-pathologies driving neurodegenerative disease. The combined dataset, when completed in 2027, is expected to encompass more than 140,000 samples profiled across multiple geographies and cohorts.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。